The priority of our ‘proof of concept’ experimental controlled trial was to assess in evolving myocardial infarction whether late HO-1 over-expression (i.e., at the time when irreversible ischemic damage is already established) is still able to improve outcome (mortality, ventricular dysfunction and left ventricular remodeling). This evidence concerns the gene HMOX1 and myocardial infarction.